Video

High Cost Drug Launches and Specialty Pharmacy

Author(s):

Lauren Santye, Assistant Editor

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Related Videos
Related Content
FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog
December 21st 2024

FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog

Aislinn Antrim, Assistant Managing Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
December 20th 2024

FDA Approves Expanded Use for Trikafta in Cystic Fibrosis

Aislinn Antrim, Assistant Managing Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
FDA Approval, Familial Chyomicronemia Syndrome | Image Credit: Tyler Olson | stock.adobe.com
December 20th 2024

FDA Approves Olezarsen as Adjunct to Diet for Familial Chylomicronemia Syndrome

Ashley Gallagher, Associate Editor